Full Text
HPR116 Expediting Reimbursement and Access for Novel Drug Indications in Europe: A Case Study on Glucagon-Like Peptide 1 (GLP-1) Agonists

Abstract

Authors

E Gomez Espinosa F Stewart M Koufopoulou

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×